论文部分内容阅读
采用介入治疗法，将９０Ｙ－ＧＴＭＳ和３２Ｐ－ＧＴＭＳ直接注入癌性肿块中，以达到杀灭癌细胞、抑制肿瘤生长、延长恶性肿瘤患者生存期的目的。在荷瘤裸鼠模型的瘤体上进行对照组、“冷”球组、不同剂量组（９０Ｙ－ＧＴＭＳ剂量分组为９２．５、１８５、３７０ＭＢｑ，３２Ｐ－ＧＴＭＳ剂量分组为３７、９２．５、１８５ＭＢｑ）的治疗，治疗后不同时间观察疗效，获得核素在单位体积中有效剂量后应用于临床。借助Ｂ超对肿瘤定位后直接穿刺注入９０Ｙ－ＧＴＭＳ，或在手术中直接将３２Ｐ－ＧＴＭＳ植入肿瘤内，并随访肿瘤大小变化。动物实验证实，瘤体为（０．２６２±０．０５０）ｃｍ３时，需９０Ｙ－ＧＴＭＳ用量＞１８５ＭＢｑ或３２Ｐ－ＧＴＭＳ用量＞９２．５ＭＢｑ作为有效剂量；核素在肿瘤中随植入时间延长，疗效更明显。临床应用中，１６例肝癌患者行Ｂ超引导下穿刺介入９０Ｙ－ＧＴＭＳ治疗和６例术中部分肿瘤介入３２Ｐ－ＧＴＭＳ治疗者，Ｂ超与ＣＴ显像见９７％癌性肿块缩小或不增大，病理示癌细胞坏死。此结果表明：９０Ｙ、３２Ｐ－ＧＴＭＳ介入治疗对失去手术治疗机会的肿瘤患者提供了有效的姑息治疗手段。
Interventional therapy, 90Y-GTMS and 32P-GTMS injected directly into cancerous masses, in order to achieve the purpose of killing cancer cells, inhibiting tumor growth and prolonging the survival of patients with malignant tumors. The control group, “cold” ball group, different dose group (90Y-GTMS dose group, 92.5,185,370MBq, 32P-GTMS dose group, 37,92.5, 185MBq) treatment, observe the curative effect at different times after treatment, and obtain the effective dose of nuclide in the unit volume and apply it to the clinic. With the help of B-ultrasound, the 90Y-GTMS was directly punctured into the tumor, or 32P-GTMS was directly implanted into the tumor during surgery. The tumor size was followed up. Animal experiments confirmed that when the tumor was (0.262 ± 0.050) cm3, the dose of 90Y-GTMS> 185MBq or the dose of 32P-GTMS> 92.5MBq was required as the effective dose. The nuclide increased with the implantation time in the tumor, The effect is more obvious. Clinical application, 16 cases of liver cancer patients under the guidance of B-guided 90Y-GTMS and 6 cases of partial tumor intervention 32P-GTMS treatment, B- and CT imaging, 97% of cancerous masses shrink or not increase The pathology showed cancer cell necrosis. The results show that: 90Y, 32P-GTMS interventional treatment of patients with the opportunity to lose the opportunity to provide an effective palliative treatment.